The Canadian market for generic semaglutide, commonly known as Ozempic, is undergoing a significant shift as Apotex Health Corp. emerges as the sole supplier of the medication for the foreseeable future. This development follows a manufacturing setback at an Indian facility that has sidelined key competitors, raising concerns over availability amidst soaring demand for the diabetes treatment.
Manufacturing Setbacks and Market Dynamics
Ozempic, produced by Danish pharmaceutical giant Novo Nordisk, was the top-selling drug in Canada last year, raking in an impressive $2.9 billion in sales, according to IQVIA Canada. The medication, which is primarily prescribed for type-2 diabetes, has seen widespread use, with over one million Canadians relying on semaglutide last year alone.
The landscape for generic semaglutide changed dramatically in January when Novo Nordisk’s market protections expired, paving the way for generic alternatives. By late April, Health Canada began granting approvals, initially to Dr. Reddy’s Laboratories from India, followed by Apotex in Toronto. A third competitor, South Africa’s Aspen Pharmacare, received approval on July 17.
However, Dr. Reddy’s recently revealed manufacturing issues at a facility being upgraded to meet the rising global demand for semaglutide. CEO Erez Israeli disclosed that the facility’s pharmaceutical ingredients contained impurities that did not meet required specifications. While the company assured investors that there was no risk to the previously supplied semaglutide, it remains unclear when the production issues will be resolved, with estimates suggesting a timeframe extending into late October or November.
Apotex Steps Up Amidst Competition Withdrawals
As a result of Dr. Reddy’s troubles, Apotex has found itself in a favourable position, becoming the only source of generic semaglutide in Canada. Catherine Thomas, the company’s vice-president of global communications, acknowledged the unexpected circumstances but emphasised their commitment to increasing supply to meet the robust demand for the more affordable medication.
Apotex’s semaglutide is produced using key ingredients sourced from India in collaboration with Orbicular Pharmaceutical Technologies. This partnership enables them to maintain a steady supply despite the current market challenges.
David Martin, managing director at Bloom Burton Securities, noted that Apotex’s situation is advantageous in the short term, predicting sales of approximately $124.4 million for the fiscal year ending March 31, 2027. This projection, however, was based on an anticipated split of market share with Dr. Reddy’s, which may no longer hold true in light of recent developments.
Pricing and Accessibility Concerns
The absence of multiple generic options could inadvertently benefit the brand-name version of Ozempic. In Canada, the pricing of generics is regulated based on agreements between insurance providers and manufacturers. For injectable medications with at least three suppliers, prices are capped at 35% of the brand-name cost. Currently, the list price for Ozempic stands at approximately £228 for a four-week supply, while generics from Apotex and Dr. Reddy’s are available for around £78, not including pharmacy markups or manufacturer discounts.
As more generic options became available, Novo Nordisk has introduced discount cards designed to help patients outside Quebec access more affordable pricing for Ozempic. However, Novo Nordisk has not provided data on how many patients have transitioned from the brand-name drug to generics.
Most pharmacies contacted reported no significant disruptions in semaglutide supply but are keeping a close eye on the situation. Youmna Rab, retail communications manager at Loblaw Companies Ltd., stated that they are currently receiving sufficient supplies to support their patients.
Tom Elliott, medical director of BCDiabetes in Vancouver, highlighted that patients have experienced limited access to generic semaglutide thus far, often opting to remain with the brand-name product.
Why it Matters
The current disruption in the generic Ozempic market underscores the fragility of pharmaceutical supply chains and the impact of manufacturing issues on patient access to crucial medications. With Apotex now the sole provider, patients may face challenges in obtaining affordable treatment options, potentially escalating healthcare costs and limiting accessibility. This situation not only highlights the necessity for robust quality control in drug manufacturing but also raises questions about the long-term sustainability of the generic market, particularly for vital medications like semaglutide.
